NeuroPace (NPCE) Scheduled to Post Quarterly Earnings on Wednesday

NeuroPace (NASDAQ:NPCE) will release its earnings data after the market closes on Wednesday, May 8th. Analysts expect NeuroPace to post earnings of ($0.32) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.10. NeuroPace had a negative return on equity of 153.76% and a negative net margin of 50.38%. The business had revenue of $18.01 million for the quarter, compared to analysts’ expectations of $17.74 million. On average, analysts expect NeuroPace to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NeuroPace Trading Down 4.0 %

NPCE opened at $12.99 on Wednesday. The business has a fifty day moving average price of $14.10 and a 200 day moving average price of $11.75. The company has a debt-to-equity ratio of 2.76, a current ratio of 5.71 and a quick ratio of 5.02. NeuroPace has a 12 month low of $3.80 and a 12 month high of $18.15. The stock has a market capitalization of $373.07 million, a price-to-earnings ratio of -10.15 and a beta of 2.09.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on NPCE. SVB Leerink started coverage on shares of NeuroPace in a report on Tuesday, January 30th. They issued an “outperform” rating and a $22.00 target price on the stock. Morgan Stanley increased their target price on NeuroPace from $9.00 to $13.00 and gave the company an “equal weight” rating in a report on Wednesday, March 6th. Cantor Fitzgerald lifted their price target on NeuroPace from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Wells Fargo & Company raised NeuroPace from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $16.00 to $20.00 in a research report on Thursday, March 14th. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of NeuroPace in a report on Tuesday, January 30th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, NeuroPace currently has an average rating of “Moderate Buy” and a consensus target price of $15.67.

Insider Activity at NeuroPace

In other NeuroPace news, major shareholder Orbimed Advisors Llc sold 461,899 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $14.49, for a total value of $6,692,916.51. Following the completion of the sale, the insider now owns 3,542,068 shares in the company, valued at $51,324,565.32. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders sold a total of 504,981 shares of company stock valued at $7,297,700 in the last three months. 27.50% of the stock is currently owned by company insiders.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.